PV
PVLA.US Palvella Therapeutics, Inc
- Market cap
- USD 2.11B
- P/E
- -
- P/B
- 10.68x
- ROE
- -42.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PVLA.US undervalued?
Graham numberThe Graham number of Palvella Therapeutics, Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Palvella Therapeutics, Inc fundamental analysis
No fundamental analysis for Palvella Therapeutics, Inc yet.
Palvella Therapeutics, Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN ra…
Full company profilePalvella Therapeutics, Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Palvella Therapeutics, Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.83M | 25.3M | 29.1M | 46.3M | 29.3M | 31.4M | 25.9M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | 29.3M | 29.1M | 23.1M | - | - | - | - |
| Operating Income | -22.8M | -14.6M | -30.8M | -27.2M | -33.9M | -51.8M | -43.5M | -11.9M | -14.1M | -38.6M | -78.6M |
| EBITDA | -22.3M | -16.2M | -26.5M | -24.4M | -34.9M | -43.4M | -30.5M | 18.7M | -13.1M | -35.9M | -81.6M |
| Net Income | -22.8M | -17.6M | -26.8M | -25.5M | -37.2M | -45.7M | -33.3M | 18.7M | -17.4M | -41.7M | -83.0M |
| EPS | -44 | -32 | -40 | -40 | -55 | -57 | -36 | 15 | -7.83 | -3.71 | -5.71 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | - | - | 105M | 154M | 16.5M | 7.55M | 88.2M | 59.6M | 239M |
| Total Liabilities | - | - | - | - | 74.0M | 103M | 39.7M | 11.4M | 25.6M | 31.6M | 41.5M |
| Shareholders' Equity | - | - | - | - | 31.0M | 50.8M | -23.2M | -3.88M | 62.6M | 28.0M | 198M |
| Cash & Short-term Investments | - | - | - | - | 70.4M | 118M | 16.1M | 7.35M | 83.6M | 58.0M | 237M |
| Total Debt | - | - | - | - | 17.0M | 14.9M | 13.1M | 78.7M | 11.9M | 633K | 485K |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | - | - | -45.9M | -7.66M | -14.8M | -13.7M | -10.8M | -25.0M | -50.8M |
| Capital Expenditure | - | - | - | - | 2.73M | 949K | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | - | -48.6M | -8.61M | -15.9M | -13.7M | -10.8M | -25.0M | -50.8M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -120.0% | -90.1% | - | - | -27.8% | -149.1% | -42.0% |
| ROA | - | - | - | - | -35.5% | -29.8% | -201.4% | 247.6% | -19.8% | -70.0% | -34.7% |
| Net Profit Margin | -391.0% | -69.8% | -91.9% | -55.0% | -127.0% | -145.6% | -128.5% | - | - | - | - |
| Debt to Equity | - | - | - | - | 0.55x | 0.29x | - | - | 0.19x | 0.02x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Palvella Therapeutics, Inc dividends
Palvella Therapeutics, Inc has not paid dividends in the last 6 fiscal years.
Last stock split: 1:80 on Apr 23, 2024.
Who owns Palvella Therapeutics, Inc
- Insiders 11.05%
- Institutions 88.95%
- Public & others 0.00%
- Shares outstanding 14.6M
- Free float 10.9M
Top funds holding PVLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 391K | 2.67% | +0.36% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 389K | 2.66% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 302K | 2.07% | 0.00% | Oct 2026 |
| PGIM Jennison Small Company A | 250K | 1.71% | +5.32% | Sep 2026 |
| Eventide Healthcare & Life Sciences I | 231K | 1.58% | 0.00% | Jun 2026 |
| Federated Hermes Kaufmann R | 215K | 1.47% | -22.44% | Sep 2026 |
| PRIMECAP Odyssey Aggressive Growth | 212K | 1.45% | +1.63% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 192K | 1.31% | 0.00% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 177K | 1.21% | -8.96% | Aug 2026 |
| Fidelity Small Cap Growth | 148K | 1.02% | +3.20% | Aug 2026 |
| T. Rowe Price New Horizons | 133K | 0.91% | -11.02% | Sep 2026 |
| Fidelity Small Cap Index | 120K | 0.82% | +0.14% | Aug 2026 |
| Federated Hermes Kaufmann Small Cap A | 114K | 0.78% | -24.18% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 112K | 0.76% | -0.38% | Oct 2026 |
| AB Small Cap Growth A | 109K | 0.74% | -2.51% | Sep 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 106K | 0.72% | 0.00% | Sep 2026 |
| Principal SmallCap Growth I Instl | 96.0K | 0.66% | +0.03% | Sep 2026 |
| Invesco Main Street Small Cap R6 | 92.5K | 0.63% | 0.00% | Sep 2026 |
| Biotech Growth Ord | 87.9K | 0.60% | -14.41% | Jul 2026 |
| Fidelity Small Cap Growth K6 | 78.2K | 0.54% | +4.24% | Aug 2026 |
Top institutions holding PVLA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 1.14M | 7.77% | -1.57% | Jun 2026 |
| Jennison Associates LLC | 961K | 6.58% | +49.95% | Jun 2026 |
| BlackRock Inc | 918K | 6.29% | +33.71% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 882K | 6.04% | 0.00% | Jun 2026 |
| First Light Asset Management, LLC | 772K | 5.28% | -21.30% | Jun 2026 |
| Bvf Inc | 673K | 4.61% | -29.99% | Jun 2026 |
| State Street Corp | 653K | 4.47% | +42.30% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 639K | 4.37% | +58.70% | Jun 2026 |
| Vanguard Capital Management, LLC | 514K | 3.52% | +7.65% | Jun 2026 |
| Frontier Capital Management CO Inc | 479K | 3.28% | +28.02% | Jun 2026 |
| Federated Hermes Inc | 433K | 2.96% | 0.00% | Jun 2026 |
| Westfield Capital Management Company, L.P. | 396K | 2.71% | 0.00% | Sep 2026 |
| Woodline Partners LP | 318K | 2.17% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 292K | 2.00% | +117.21% | Jun 2026 |
| Geode Capital Management, LLC | 276K | 1.89% | +34.32% | Jun 2026 |
| PRIMECAP Management Company | 269K | 1.84% | +4.85% | Sep 2026 |
| Siren, L.L.C. | 257K | 1.76% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 253K | 1.73% | -3.68% | Jun 2026 |
| Eventide Asset Management, LLC | 231K | 1.58% | -0.76% | Jun 2026 |
| Emerald Advisers, LLC | 229K | 1.57% | -0.04% | Sep 2026 |
Palvella Therapeutics, Inc company profile
- Company name
- Palvella Therapeutics, Inc
- Ticker
- PVLA.US
- Exchange
- USA Stocks
- Listed since
- Dec 16, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Fiscal year end
- December
- Address
- 353 W. Lancaster Avenue, Wayne, PA, United States, 19087
- Phone
- 484 253 1461
- Website
- palvellatx.com
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc management
10- Mr. Wesley H. KaupinenFounder, President, CEO & Director
- Mr. Matthew E. KorenbergCFO, Corporate Secretary & Treasurer · born 1975
- Ms. Kathleen GoinChief Operating Officer · born 1971
- Dr. Jeffrey Martini Ph.D.Chief Scientific Officer · born 1978
- Ms. Marcy B. NanusVice President of Investor Relations & Corporate Affairs
- Ms. Colleen Kelly J.D.VP & Head of Legal
- Ms. Bohan WeiVice President of Corporate Development & New Product Planning
- Mr. Kent TaylorSenior Vice President of Sales
- Ms. Sarah FosterSenior Vice President of Human Resources
- Ms. Emily CookSenior Vice President of Clinical Operations